|
1) Derkx F, Schalekamp M. Human prorenin: pathophysiology and clinical implications. Clin Exp Hypertens. 1988; A10: 1213-25
|
|
|
|
|
2) Peters J, Farrenkopf R, Clausmeyer S, et al. Functional significance of prorenin internalization in the rat heart. Circ Res. 2002; 90: 1135- 41
|
|
|
|
|
3) Veniant M, Menard J, Bruneval P, et al. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest. 1996; 98: 1966-70
|
|
|
|
|
|
4) Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002; 109: 1417-27
|
|
|
|
|
|
5) Suzuki F, Hayakawa M, Nakagawa T, et al. Human prorenin has “gate and handle" regions for its non-proteolytic activation. J Biol Chem. 2003; 278: 22217-22
|
|
|
|
|
|
6) Nabi AHMN, Kageshima A, Uddin M, et al. Binding properties of rat prorenin and renin to the recombinant rat renin/prorenin receptor prepared by a baculovirus expression system. Int J Mol Med. 2006; 18: 483-8
|
|
|
|
|
|
7) Ichihara A, Suzuki F, Nakagawa T, et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor deficient mice. J Am Soc Nephrol. 2006; 17: 1950-61
|
|
|
|
|
|
8) Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-b1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006; 69: 105-13
|
|
|
|
|
|
9) Huang Y, Noble N, Zhang J, et al. Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int. 2007; 72: 42-52
|
|
|
|
|
|
10) Saris J, 'tHoen P, Garrelds I, et al. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension. 2006; 48: 564-71
|
|
|
|
|
|
11) Sakoda M, Ichihara A, Kaneshiro Y, et al. (Pro)renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. Hyper Res. 2007; 30: 1139-46
|
|
|
|
|
|
12) Achard V, Boullu-Ciocca S, Desbriere R, et al. Renin receptor expression in human adipose tissue. Am J Physiol. 2007; 292: R274-82
|
|
|
|
|
|
13) Schefe J, Menk M, Reinemund J, et al. A Novel signal transduction cascade involving direct physical interaction of the renin/prorenin recep-tor with the transcription factor promyelocytic zinc finger protein. Circ Res. 2006; 99: 1355-66
|
|
|
|
|
|
14) Ichihara A, Hayashi M, Kaneshiro Y, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle" region for non-proteolytic activation of prorenin. J Clin Invest. 2004; 114: 1128-35
|
|
|
|
|
|
15) Nabi AHMN, Uddin M, Nakagawa T, et al. Role of “handle" region of prorenin prosegment in the non-proteolytic activation of prorenin by binding to membrane anchored (pro)renin receptor. Front Biosci. 2007; 12: 4810-7
|
|
|
|
|
|
16) Kaneshiro Y, Ichihara A, Sakoda M, et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human-renin/prorenin-receptor-transgenic rats. J Am Soc Nephrol. 2007; 18: 1789-95
|
|
|
|
|
|
17) Ichihara A, Kaneshiro Y, Takemitsu T, et al. Non-proteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension. 2006; 47: 894-900
|
|
|
|
|
|
18) Ichihara A, Kaneshiro Y, Takemitsu T, et al. Contribution of non-proteolytically activated prorenin in glomeruli to hypertensive renal damage. J Am Soc Nephrol. 2006; 17: 2495-503
|
|
|
|
|
|
19) Wilson D, JA L. Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. N Engl J Med. 1990; 323: 1101-6
|
|
|
|
|